| Heading: |
Blood Cancer: Medical Treatments |
| Question ID: |
1751098 |
| UIN: |
21022 |
| House: |
Commons |
| Date tabled: |
2024-12-18 |
| Asking Member ID: |
4764 |
| Asking Member display name: |
Bell Ribeiro-Addy
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Bell Ribeiro-Addy
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS preparedness for the next generation of blood cancer treatments. |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-01-07 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
1506 |
| Answering Member display name: |
Andrew Gwynne
|
| Answering Member handle: |
GwynneMP
|
| Answering Member Twitter reference: |
@GwynneMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
We are committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials, to ensure that innovative, lifesaving treatments are accessible to National Health Service patients, including those with blood cancer.T... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |